Skip to main content

Month: August 2024

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) —  Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem” or the “Company”), today reported financial results for the quarter ended June 30, 2024 and provided a business update. “Following the close of the Tenet Medicines acquisition and the concurrent financing, we believe Eliem is well-positioned as we transition...

Continue reading

FutureFuel Announces Appointment of New Director

CLAYTON, Mo., Aug. 14, 2024 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel” or the “Company”), a manufacturer of custom and performance chemicals and biofuels, announced today that its Board of Directors (the “Board”) appointed Richard P. Rowe effective August 13, 2024 as a Class B member of the Board until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Rowe has served as President of RPR Global Solutions, LLC, an advisory firm that provides advisory services to companies in the specialty chemicals and materials industries, since February 2022. After serving in various leadership positions for over 20 years at Arkema, S.A., a multi-national manufacturer of specialty materials and chemicals, Mr. Rowe served as President and Chief Executive Officer of Arkema Inc.,...

Continue reading

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$25.9 million in cash and cash equivalents as of June 30, 2024; cash runway into the third quarter of 2025FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended June 30, 2024, and highlighted updates for its pipeline. “Thus far in 2024, we have announced promising preliminary results from our vebreltinib program for the treatment of various tumors with Met...

Continue reading

European Wax Center Board of Directors Appoints David Berg as Chief Executive Officer

Industry veteran David Berg has served as Executive Chairman of European Wax Center since 2023 and previously served as Chief Executive Officer from 2018 to 2023 PLANO, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Today, European Wax Center, Inc. (NASDAQ: EWCZ) (the “Company” or “European Wax Center”), the largest and fastest-growing franchisor and operator of out-of-home waxing services in the United States, announced that the Board of Directors has appointed David Berg as Chief Executive Officer (CEO), effective August 12, 2024. Mr. Berg succeeds David Willis, who served as CEO and previously held various positions including President, Chief Operating Officer and Chief Financial Officer. Mr. Berg has served as Executive Chairman of European Wax Center since September 2023 and will remain in this role. He previously served as CEO from...

Continue reading

Katapult Grows Second Quarter Revenue 9% Year-Over-Year

Seventh Consecutive Quarter of Year-Over-Year Gross Originations Growth Reiterates Full Year 2024 Outlook For At Least 10% Gross Originations and Revenue Growth PLANO, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT), an e-commerce-focused financial technology company, today reported its financial results for the second quarter ended June 30, 2024. “We grew the business across our key financial and operating metrics year-over-year – gross originations, revenue and Adjusted EBITDA – and continued to make strong progress on our growth strategy,” said Orlando Zayas, CEO of Katapult. “Despite the macro headwinds in the home furnishings category, our non-Wayfair gross originations, which were 52% of our base this quarter, grew nearly 20% and total Katapult Pay(R)...

Continue reading

Novaturas will introduce half year results for 2024 (unaudited)

On August 23rd 2024 at 9:00 AM CEO of AB “Novaturas” Mr. Kristijonas Kaikaris and interim CFO Ms. Aukse Kriauciunaite will present Company’s consolidated financial results for half year of 2024 for the investors. We kindly ask to register for the webinar using the link below: https://nasdaq.zoom.us/webinar/register/WN_P6ZNaZR9QGS085aJNoasiQ Interim CFO Aukse Kriauciunaite +370 630 37367

Continue reading

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be available for replay on ALK’s website https://ir.alk.net Conference call If you wish to participate via telephone, please register for the conference call by using this link: Registration – ALK H1 (Q2) 2024 – telephone conference and follow the instructions. You will receive an email from diamondpass@choruscall.com...

Continue reading

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on Aug. 13, 2024. The gross proceeds from this offering are expected to be approximately $100 million, before deducting underwriting discounts, commissions and other offering expenses payable by Anaptys. All of the shares of common stock are being offered by Anaptys. The offering is expected to close on or about Aug. 15, 2024, subject to the...

Continue reading

North Media announces preliminary financial results for Q2 2024 and revises its full-year guidance for 2024

Announcement no. 10/202414 August 2024 The preliminary financial results for Q2 and therefore also H1 2024 were in line with expectations. Accordingly, the Group is adjusting its full-year guidance for consolidated revenue to the DKK 1,320-1,365m range (previously DKK 1,310-1,355m). FK Distribution is expected to drive the revenue improvement. At the same time, North Media is lowering its full-year EBITDA and EBIT guidance for 2024. The Group now expects EBITDA to be in the DKK 150-175m range (previously DKK 170-200m) and EBIT to be in the DKK 75-100m range (previously DKK 95-125m). The guidance is revised as a result of two decisions:to accelerate the implementation of automated packing and technologies for sorting, packing and distributing door drop media in SDR Svensk Direktreklam. The implementation is expected to be completed by...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.